<?xml version="1.0" encoding="UTF-8"?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1" xml:lang="zh" xsi:noNamespaceSchemaLocation="https://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1.xsd"><front><journal-meta><!-- 出版商赋予期刊ID--><journal-id journal-id-type="publisher-id">YIKE</journal-id><journal-title-group><!-- 期刊中文全称--><journal-title>安徽医科大学学报</journal-title><!-- 期刊英文全称--><journal-title xml:lang="en">Acta Universitatis Medicinalis Anhui</journal-title><!-- 期刊英文缩写--><abbrev-journal-title abbrev-type="publisher" xml:lang="en">Acta Universitatis Medicinalis Anhui</abbrev-journal-title><!-- 期刊中文缩写--><abbrev-journal-title abbrev-type="publisher">安徽医科大学学报</abbrev-journal-title></journal-title-group><!-- 期刊ISSN号--><issn pub-type="ppub">1000-1492</issn><!-- 期刊CN号--><issn pub-type="cn">34-1065/R</issn><publisher><!--出版商英文名称【预置实体】 待确认 --><publisher-name xml:lang="en">Anhui Lianzhong Printing Limited Company</publisher-name><!--出版商英文地址【预置实体】 --><publisher-loc xml:lang="en">Editorial Board of Acta Universitatis Medi-cinalis Anhui Meishan Road , Hefei 230032</publisher-loc><!-- 出版商中文名称【预置实体】--><publisher-name>《安徽医科大学学报》编辑部</publisher-name><!--出版商中文地址【预置实体】 --><publisher-loc>安徽省合肥市安徽医科大学校内老图书馆三楼</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1000–1492（2026）03–0448–07</article-id><article-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009</article-id><article-id pub-id-type="manuscript">V234 李容</article-id><article-categories><subj-group subj-group-type="clc"><subject>R 285.5</subject></subj-group><subj-group subj-group-type="dc"><subject>A</subject></subj-group><subj-group subj-group-type="heading"><subject>基础医学研究</subject></subj-group></article-categories><title-group><article-title>ARTN在前列腺癌中的表达及临床意义</article-title><trans-title-group xml:lang="en"><trans-title>Expression and clinical significance of ARTN in prostate cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>李</surname><given-names>容</given-names></name><name name-style="eastern" xml:lang="en"><surname>Li</surname><given-names>Rong</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="author-notes" rid="fna1"/></contrib><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>井</surname><given-names>俊峰</given-names></name><name name-style="eastern" xml:lang="en"><surname>Jing</surname><given-names>Junfeng</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern"><surname>魏</surname><given-names>灿</given-names></name><name name-style="eastern" xml:lang="en"><surname>Wei</surname><given-names>Can</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/><xref ref-type="author-notes" rid="fna2"/></contrib><aff-alternatives id="aff1"><aff><institution>安徽医科大学附属合肥医院（合肥市第二人民医院）泌尿外科</institution>，<city>合肥</city>  <postal-code>230011</postal-code></aff><aff xml:lang="en"><institution>［Department of Urology， Hefei Hospital Affiliated to Anhui Medical University （The Second People's Hospital of Hefei）， Hefei    230011］</institution></aff></aff-alternatives></contrib-group><author-notes><corresp xml:lang="en" id="cor1"><named-content content-type="corresp-name">Wei Can</named-content>，E-mail： <email>aydweican@163.com</email></corresp><fn fn-type="other" specific-use="about-author" id="fna1"><p><named-content content-type="corresp-name">李  容</named-content>，女，硕士研究生</p></fn><fn fn-type="other" specific-use="about-author" id="fna2"><p><named-content content-type="corresp-name">魏  灿</named-content>，男，博士，副教授，硕士生导师，通信作者，E-mail： <email>aydweican@163.com</email></p></fn></author-notes><pub-date pub-type="epub" iso-8601-date="2026-02-09T08：52：07"><day>09</day><month>02</month><year>2026</year></pub-date><pub-date pub-type="ppub"><day>23</day><month>03</month><year>2026</year></pub-date><volume>61</volume><issue>3</issue><issue-id>14</issue-id><fpage>448</fpage><lpage>454</lpage><page-range>448-454</page-range>  <history><date date-type="received"> <day>22</day><month>11</month><year>2025</year></date>  </history>  <abstract abstract-type="key-points"><sec><title>目的</title><p>探讨神经鞘胚素（ARTN）蛋白在前列腺癌（PCa）组织中表达的临床意义及其对PCa细胞系恶性行为的影响。</p></sec><sec><title>方法</title><p>免疫组化法检测40例良性前列腺组织与91例PCa组织中ARTN蛋白的表达情况，并分析其与PCa临床病理特征的关系。构建敲低ARTN的PCa稳转细胞系，通过CCK-8细胞增殖实验、Transwell实验检测ARTN对PCa细胞增殖、迁移和侵袭能力的影响。运用Western blot实验检测ARTN对上皮-间质转化（EMT）相关标志物钙黏蛋白E（E-cadherin）、钙黏蛋白N（N-cadherin）、波形蛋白（Vimentin）和蜗牛家族转录抑制因子1（Snail-1）表达的影响。</p></sec><sec><title>结果</title><p>ARTN在PCa中高表达并且与Gleason评分、局部淋巴结转移和局部神经侵犯具有相关性（<italic>P</italic>0.05）。生存分析显示，ARTN表达阳性和阴性患者的生存期差异有统计学意义（<italic>P</italic>=0.027）。CCK-8实验和Transwell实验结果显示，敲低ARTN可抑制PCa细胞的增殖、迁移和侵袭能力（均<italic>P</italic>0.05）；Western blot结果显示，敲低ARTN后PCa细胞的上皮标志物E-cadherin上调，而间充质标志物N-cadherin、Snail-1和Vimentin下调。</p></sec><sec><title>结论</title><p>ARTN在PCa中高表达并能够促进肿瘤细胞的增殖、迁移、侵袭能力和EMT水平，ARTN可能是PCa诊断和治疗的潜在靶点。</p></sec></abstract><trans-abstract abstract-type="key-points" xml:lang="en"><sec><title>Objective</title><p>To explore the clinical significance of artemin （ARTN） expression in prostate cancer （PCa） tissues and its impact on the malignant behavior of PCa cell lines.</p></sec><sec><title>Methods</title><p>Immunohistochemistry was used to detect the expression of ARTN protein in 40 benign prostate tissues and 91 PCa tissues， and its relationship with the clinical and pathological characteristics of PCa was analyzed. PCa stable cell lines with ARTN knockdown were constructed， and the effects of ARTN on the proliferation， migration， and invasion ability of PCa cells were detected <italic>via </italic>CCK-8 cell proliferation assay and Transwell assay. Western blot assay was used to detect the effect of ARTN on the expression of epithelial-mesenchymal transition （EMT） related markers E-cadherin， N-cadherin， Vimentin， and Snail family transcription inhibitory factor 1 （Snail-1）.</p></sec><sec><title>Results</title><p>ARTN was highly expressed in PCa and correlated with Gleason score， local lymph node metastasis， and local nerve invasion （<italic>P</italic>0.05）. Survival analysis showed a statistically significant difference in survival rates between ARTN positive and negative patients （<italic>P</italic>=0.027）. The results of CCK-8 and Transwell assay showed that the knockdown of ARTN could inhibit the proliferation， migration， and invasion ability of PCa cells （all <italic>P</italic>0.05）. Western blot results showed that the knockdown of ARTN upregulated the epithelial marker E-cadherin in PCa cells， while the mesenchymal markers N-cadherin， Snail-1， and Vimentin were downregulated.</p></sec><sec><title>Conclusion</title><p>ARTN is highly expressed in PCa and can promote the proliferation， migration， invasion ability of PCa cells， as well as increasing EMT levels in PCa cells， suggesting it may be a potential target for the diagnosis and treatment of PCa.</p></sec></trans-abstract><kwd-group kwd-group-type="author"><kwd>神经鞘胚素</kwd><kwd>前列腺恶性肿瘤</kwd><kwd>生存率</kwd><kwd>预后</kwd><kwd>上皮-间质转化</kwd><kwd>生物标志物</kwd></kwd-group><kwd-group xml:lang="en" kwd-group-type="author"><kwd>artemin</kwd><kwd>prostate cancer</kwd><kwd>survival rate</kwd><kwd>prognosis</kwd><kwd>epithelial-mesenchymal transition</kwd><kwd>biomarker</kwd></kwd-group><funding-group><award-group><funding-source>国家自然科学基金项目</funding-source><award-id>82004010</award-id></award-group><award-group><funding-source>安徽省重点研究与开发计划项目</funding-source><award-id>2022e07020061</award-id></award-group><award-group><funding-source>合肥市自然科学基金项目</funding-source><award-id>HZR2445</award-id></award-group><funding-statement>国家自然科学基金项目（编号：82004010）；安徽省重点研究与开发计划项目（编号：2022e07020061）；合肥市自然科学基金项目（编号：HZR2445）</funding-statement></funding-group><funding-group xml:lang="en"><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82004010</award-id></award-group><award-group><funding-source>Key Research and Development Program of Anhui Province</funding-source><award-id>2022e07020061</award-id></award-group><award-group><funding-source>Natural Science Foundation of Hefei</funding-source><award-id>HZR2445</award-id></award-group><funding-statement>National Natural Science Foundation of China （No. 82004010）；Key Research and Development Program of Anhui Province （No. 2022e07020061）；Natural Science Foundation of Hefei （No. HZR2445）</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><equation-count count="0"/><ref-count count="16"/><page-count count="7"/><word-count count="15370"/></counts><custom-meta-group><custom-meta><meta-name>version</meta-name><meta-value>1.0.0.25071</meta-value></custom-meta><custom-meta><meta-name>structure-time</meta-name><meta-value>2026-05-25T09:36:44</meta-value></custom-meta><custom-meta><meta-name>word-source</meta-name><meta-value>FX</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>前列腺癌（prostate cancer，PCa）是最常见的恶性肿瘤之一，在欧美发达国家高居男性癌症发病率的第一位<sup>［<xref ref-type="bibr" rid="R1">1</xref>］</sup>，近年来PCa在中国的发病率也迅速增高，并呈现发病年轻化趋势<sup>［<xref ref-type="bibr" rid="R2">2</xref>］</sup>，超过50%的患者在初次确诊即已出现局部进展或转移，失去最佳的手术时机，药物保守治疗最终会进入去势抵抗期，预后极差<sup>［<xref ref-type="bibr" rid="R3">3</xref>］</sup>，因此，深入研究PCa的发病机制并探索新的治疗靶点具有重要的意义。</p><p>神经鞘胚素（artemin，ARTN）是胶质细胞源性神经营养因子（glial cell line-derived neurotrophic factor，GDNF）家族的第4个成员，在神经细胞的发育和轴突的迁移过程中起重要的调节作用<sup>［<xref ref-type="bibr" rid="R4">4</xref>］</sup>。有研究<sup>［<xref ref-type="bibr" rid="R5">5</xref>］</sup>显示，ARTN在多种人类恶性肿瘤细胞中都有高表达，并与肿瘤的侵袭性相关，然而ARTN对PCa的影响却罕有报道。本实验研究了ARTN在PCa中表达的临床意义，并探究其对癌细胞恶性行为的影响，旨在为PCa的诊疗提供新靶点。</p><sec id="s1"><label>1</label><title>材料与方法</title><sec id="s1a"><label>1.1</label><title>材料</title><sec id="s1a1"><label>1.1.1</label><title>组织标本</title><p specific-use="noneIndent">收集2016年7月—2024年6月在合肥市第二人民医院泌尿外科收治的91例PCa患者的临床病理资料及组织蜡块。所有患者均经组织穿刺或手术切除病理明确诊断，患者年龄为62～84岁，平均年龄72.5岁，随访患者的生存情况。收集同期40例良性前列腺增生症患者（平均年龄70.7岁）的手术组织蜡块，进行对比研究。截至最后随访时间2025年3月，全部患者中位随访时间45.3个月（10～104个月）。本研究经安徽医科大学生物医学伦理委员会审批（批准号：20200701）。</p></sec><sec id="s1a2"><label>1.1.2</label><title>细胞系和主要试剂</title><p specific-use="noneIndent">人PCa细胞系（LNCaP细胞和PC3细胞）均购自美国典型培养物保藏中心。两种细胞均用含RPMI 1640+10%胎牛血清+1%双抗的培养基，在37 ℃恒温无菌培养箱、5%CO<sub>2</sub>、相对饱和湿度95%的条件下培养。RPMI1640培养基（PM150110）、青-链霉素双抗（PB180120）购自武汉普诺赛生命科技有限公司，胎牛血清（A5256701）购自美国Thermo Fisher公司，兔抗人ARTN抗体（MA563305）、Lipofectamine 3000转染试剂盒（L3000015）购自美国Invitrogen公司，即用型免疫组化试剂盒（KIT-9720）购自福州迈新生物技术有限公司，通用型总RNA快速提取试剂盒（ROA3301-01）、逆转录试剂盒（R412-01）购自南京诺唯赞生物科技股份有限公司，E-cadherin抗体（BM3903）、N-cadherin抗体（BM3921）、Snail-1抗体（PB0449）购自武汉博士德生物工程有限公司，Vimentin抗体（AF1975）、GAPDH（AF1186）购自上海碧云天生物技术有限公司，CCK-8细胞活性检测试剂盒（40203ES76）购自上海翌圣生物科技股份有限公司，Transwell小室购自美国Corning公司，siRNA、PCR引物由上海吉玛制药技术有限公司合成。</p></sec></sec><sec id="s1b"><label>1.2</label><title>方法</title><sec id="s1b1"><label>1.2.1</label><title>细胞培养和转染</title><p specific-use="noneIndent">将LNCaP和PC3细胞复苏并传代培养后，两种细胞均以每孔5.0× 10<sup>4</sup>的数量接种于6孔板，细胞密度达70%~80%时进行转染，操作步骤严格按照Lipofectamine 3000转染试剂说明书进行。根据Genebank中登记的<italic>ARTN</italic>基因mRNA序列（基因号：NM057090）设计siRNA干扰序列，并由上海吉玛制药技术有限公司合成。设置si-control组为阴性对照组、siARTN-1组和siARTN-2组为实验组，各组采用相应的siRNA进行转染。转染序列如下：阴性对照组（si-control）为5′-UUCAC UCCAAGUCUCUUCC-3′；实验组1（siARTN-1）为5′-GCGGUCUCCUUCAUGGACG-3′；实验组2（siARTN-2）为5′-GAGCACCUGGAGAACCGUG-3′。镜下观察细胞生长状态，转染48 h后，通过Western blot检测两种siRNA的敲低效率，收集细胞并进行后续实验。</p></sec><sec id="s1b2"><label>1.2.2</label><title>免疫组织化学（immunohistochemistry，IHC）染色和评分</title><p specific-use="noneIndent">操作步骤严格按照即用型免疫组化试剂盒说明书进行。一抗ARTN抗体工作为浓度1∶100，组织切片经脱蜡、水化、H<sub>2</sub>O<sub>2</sub>孵育、抗原修复、封闭后，一抗4 ℃孵育过夜，二抗37 ℃孵育30 min，再进行DAB显色、苏木精复染、脱水、透明、树胶封片、烘干后镜下观察。免疫组化染色结果经高年资病理科医师独立阅片和评分。评分方法和阳性标准参照张鹤瑞 等<sup>［<xref ref-type="bibr" rid="R6">6</xref>］</sup>的报道，采用双评分半定量法评分，得分4分计为阴性，得分≥4分为阳性。</p></sec><sec id="s1b3"><label>1.2.3</label><title>PCR实验</title><p specific-use="noneIndent">采用RNA提取试剂盒提取各组细胞的RNA，检测总RNA浓度和纯度合格后，逆转录试剂盒将RNA反转录为cDNA。以cDNA为模板，进行实时荧光定量PCR。预变性：95 ℃、30 s。循环扩增40次：95 ℃、10 s，60 ℃、30 s。溶解曲线：95 ℃、15 s，60 ℃、60 s，95 ℃、15 s。采用相对定量法2<sup>-ΔΔ</sup><italic><sup>C</sup></italic><inline-formula><alternatives><mml:math id="M1"><mml:msub><mml:mrow/><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub></mml:math><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-M001.jpg"><?fx-imagestate width="1.26999998" height="4.23333359"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-M001c.jpg"><?fx-imagestate width="1.26999998" height="4.23333359"?></graphic></alternatives></inline-formula>计算ARTN mRNA的表达情况。以GAPDH作为内参，基因引物序列：ARTN上游引物5′-GTC TACAAACTCAACTCCCGGTTT-3′，下游引物5′-CC CTCGGATATGGAGAGTAGAGAA-3′；GAPDH上游引物5′-GCACCGTCAAGGCTGAGAAC-3′，下游引物5′-TGGTGAAGACGCCAGTGGA-3′。</p></sec><sec id="s1b4"><label>1.2.4</label><title>CCK-8细胞增殖实验</title><p specific-use="noneIndent">收集各组转染后的细胞，用完全培养基重悬制成单细胞悬液。调整细胞密度为3×10<sup>4</sup>个/mL，每孔取100 μL细胞悬液，均匀接种于96孔板中，继续培养，分别于12、24、48 h后，加入CCK-8试剂孵育30 min，采用酶标仪测量每孔450 nm波长下的吸光度 <italic>A</italic>值。</p></sec><sec id="s1b5"><label>1.2.5</label><title>Transwell细胞迁移实验</title><p specific-use="noneIndent">收集各组转染后的细胞，用不含血清的培养基重悬细胞。调整细胞浓度为4×10<sup>4</sup>个/mL，将细胞均匀接种于24孔板中Transwell小室的上室，每孔200 μL，下室每孔加500 μL含10%血清的培养基，培养24 h，弃去上室和下室中的培养液，经4%多聚甲醛固定、结晶紫染、PBS洗涤后，用棉签擦除上室细胞，每孔选取3个视野进行细胞计数。</p></sec><sec id="s1b6"><label>1.2.6</label><title>Transwell细胞侵袭实验</title><p specific-use="noneIndent">将基质胶用不含血清的培养基稀释后，均匀铺在Transwell小室底部膜的上室面，2 h后，将各组细胞以6×10<sup>4</sup>个/mL的浓度接种于Transwell小室的上室，每孔200 μL，其余步骤同细胞迁移实验。</p></sec><sec id="s1b7"><label>1.2.7</label><title>Western blot实验</title><p specific-use="noneIndent">收集各组细胞，用胰酶消化细胞并离心，收集细胞沉淀，加入PIPA裂解液在冰上裂解20 min，离心收集上清液，BCA法测定蛋白浓度。加蛋白上样缓冲液后，99 ℃水浴加热10 min进行蛋白变性。上样20 μg蛋白行SDS-PAGE凝胶电泳，将凝胶上的蛋白转移至PVDF膜。5%脱脂牛奶室温封闭1 h，加一抗4 ℃孵育过夜，TBST洗膜后，常温孵育二抗1 h后，再次TBST充分洗膜，滴加ECL进行暗室显影拍摄。</p></sec></sec><sec id="s1c"><label>1.3</label><title>统计学处理</title><p specific-use="noneIndent">实验数据采用SPSS 27.0和GraphPad Prism 8.0软件进行分析。计量数据以<inline-formula><alternatives><mml:math id="M2"><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-M002.jpg"><?fx-imagestate width="1.77800000" height="2.62466669"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-M002c.jpg"><?fx-imagestate width="1.77800000" height="2.62466669"?></graphic></alternatives></inline-formula><italic>±s</italic>表示，两样本率的比较采用卡方检验，Kaplan-Meier法绘制生存曲线，两组间比较使用<italic>ｔ</italic>检验。所有实验均独立重复3次，以<italic>P</italic>0.05为差异有统计学意义。</p></sec></sec><sec id="s2"><label>2</label><title>结果</title><sec id="s2a"><label>2.1</label><title>ARTN在PCa及前列腺良性组织中的表达</title><p>IHC结果显示，ARTN蛋白在PCa组织的肿瘤细胞中普遍高表达，主要表达在细胞膜和细胞质，局部胞质呈现强阳性，见<xref ref-type="fig" rid="F1">图1</xref>A；而在前列腺良性增生组织的细胞中呈低表达，见<xref ref-type="fig" rid="F1">图1</xref>B。ARTN在PCa组织中表达率为（52/91，57.14%），高于前列腺良性增生组（14/40，35.00%），两组间的表达率差异有统计学意义（<italic>P</italic>0.05）。</p><fig position="float" id="F1"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.F001</object-id><label>图1</label><caption><title>ARTN在PCa组织和良性前列腺组织中的表达    IHC×200</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig. 1</label><title>Expression of ARTN in PCa tissue and benign prostate tissue    IHC×200</title></abstract><abstract abstract-type="note"><p>A： Expression of ARTN in PCa tissue； B： Expression of ARTN in benign prostate tissue.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F001.eps" id="Graphic1"><?fx-imagestate width="70.20277405" height="27.86944389"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F001.jpg"><?fx-imagestate width="70.20277405" height="27.86944389"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F001c.jpg"><?fx-imagestate width="70.20277405" height="27.86944389"?></graphic></alternatives></fig></sec><sec id="s2b"><label>2.2</label><title>ARTN在PCa组织中表达的临床意义</title><p specific-use="noneIndent">将ARTN蛋白表达水平与PCa患者的临床病理资料进行分析。结果显示，相较于低表达患者，ARTN高表达患者的 Gleason 评分更高（<italic>P</italic>=0.028），易于出现局部淋巴结转移（<italic>P</italic>=0.007）和局部神经侵犯（<italic>P</italic>=0.044）。ARTN的表达水平与患者的年龄（<italic>P</italic>=0.671）、PSA值（<italic>P</italic>=0.096）和TNM分期（<italic>P</italic>=0.403）等无明显相关性（<italic>P</italic>0.05），见<xref ref-type="table" rid="T1">表1</xref>。Kaplan-Meier生存分析结果显示，ARTN高表达患者的生存曲线在各个时间段均低于低表达患者（<xref ref-type="fig" rid="F2">图2</xref>），提示高表达患者总体生存率较低，Log-Rank检验显示，两组之间生存率差异有统计学意义（<italic>P</italic>=0.027）。</p><table-wrap id="T1"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.T001</object-id><label>表1</label><caption><p>ARTN的表达水平与临床病理参数之间的关系</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab. 1</label><title>Relationship between ARTN expression leveland clinical pathological features</title></abstract><alternatives><table id="Table1"><thead><tr><th align="left" rowspan="2" style="border-top:solid;border-bottom:solid;">Item</th><th align="center" rowspan="2" style="border-top:solid;border-bottom:solid;"><italic>n</italic>（91）</th><th align="center" colspan="2" style="border-top:solid;border-bottom:solid;">Expression level</th><th align="center" rowspan="2" style="border-top:solid;border-bottom:solid;">χ<sup>2</sup> value</th><th align="center" rowspan="2" style="border-top:solid;border-bottom:solid;"><italic>P </italic>value</th></tr><tr><th align="center" style="border-bottom:solid;"><p>High</p><p>（<italic>n</italic>=52）</p></th><th align="center" style="border-bottom:solid;"><p>Low</p><p>（<italic>n</italic>=39）</p></th></tr></thead><tbody><tr align="center"><td align="left">Age（year）</td><td align="left"/><td align="left"/><td align="left"/><td align="center">0.181</td><td align="center">0.671</td></tr><tr align="center"><td align="left" style="text-indent:1em;">≥70</td><td align="center">42</td><td align="center">23</td><td align="center">19</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" style="text-indent:1em;">70</td><td align="center">49</td><td align="center">29</td><td align="center">20</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">PSA（ng/mL）</td><td align="left"/><td align="left"/><td align="left"/><td align="center">2.767</td><td align="center">0.096</td></tr><tr align="center"><td align="left" style="text-indent:1em;">10</td><td align="center">37</td><td align="center">25</td><td align="center">12</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" style="text-indent:1em;">≤10</td><td align="center">54</td><td align="center">27</td><td align="center">27</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">Gleason score</td><td align="left"/><td align="left"/><td align="left"/><td align="center">4.818</td><td align="center">0.028</td></tr><tr align="center"><td align="left" style="text-indent:1em;">7</td><td align="center">40</td><td align="center">28</td><td align="center">12</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" style="text-indent:1em;">≤7</td><td align="center">51</td><td align="center">24</td><td align="center">27</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left">TNM stage</td><td align="left"/><td align="left"/><td align="left"/><td align="center">0.700</td><td align="center">0.403</td></tr><tr align="center"><td align="left" style="text-indent:1em;">T1-T2</td><td align="center">61</td><td align="center">33</td><td align="center">28</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" style="text-indent:1em;">T3-T4</td><td align="center">30</td><td align="center">19</td><td align="center">11</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" colspan="3"><p>Local lymph node</p><p>metastasis</p></td><td align="left"/><td align="center">7.354</td><td align="center">0.007</td></tr><tr align="center"><td align="left" style="text-indent:1em;">No</td><td align="center">66</td><td align="center">32</td><td align="center">34</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" style="text-indent:1em;">Yes</td><td align="center">25</td><td align="center">20</td><td align="center">5</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" colspan="2">Local nerve invasion</td><td align="left"/><td align="left"/><td align="center">4.044</td><td align="center">0.044</td></tr><tr align="center"><td align="left" style="text-indent:1em;">No</td><td align="center">70</td><td align="center">36</td><td align="center">34</td><td align="left"/><td align="left"/></tr><tr align="center"><td align="left" style="border-bottom:solid;text-indent:1em;">Yes</td><td align="center" style="border-bottom:solid;">21</td><td align="center" style="border-bottom:solid;">16</td><td align="center" style="border-bottom:solid;">5</td><td align="left" style="border-bottom:solid;"/><td align="left" style="border-bottom:solid;"/></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-T001.jpg"><?fx-imagestate width="81.19583893" height="104.64012909"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-T001c.jpg"><?fx-imagestate width="81.19583893" height="104.64012909"?></graphic></alternatives></table-wrap><fig position="float" id="F2"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.F002</object-id><label>图2</label><caption><title>ARNT高表达与低表达患者的生存曲线</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig. 2</label><title>Survival curves of patients with high andlow ARNT expression</title></abstract><alternatives><graphic specific-use="print" xlink:href="media/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F002.eps" id="Graphic2"><?fx-imagestate width="65.96945190" height="54.68054962"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F002.jpg"><?fx-imagestate width="65.96945190" height="54.68054962"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F002c.jpg"><?fx-imagestate width="65.96945190" height="54.68054962"?></graphic></alternatives></fig></sec><sec id="s2c"><label>2.3</label><title>构建ARTN低表达的PCa细胞株</title><p specific-use="noneIndent">qRT-PCR结果显示，在LNCaP细胞中，转染后si-control组、siARTN-1组和siARTN-2组ARTN-mRNA表达量分别为1.217±0.080、0.304±0.037、0.318±0.034，实验组与对照组比较差异均有统计学意义（<italic>P</italic>0.01）。在PC3细胞中，转染后si-control组、siARTN-1组和siARTN-2组ARTN-mRNA表达量分别为1.276±0.043、0.150±0.018、0.209±0.016，实验组与对照组比较差异均有统计学意义（<italic>P</italic>0.01）。Western blot检测结果显示，在LNCaP（<xref ref-type="fig" rid="F3">图3</xref>A）和PC3（<xref ref-type="fig" rid="F3">图3</xref>B）细胞系中，实验组ARTN蛋白表达水平均低于相应的对照组。以上结果表明，通过siRNA干预，成功构建了稳定低表达ARTN的LNCaP和PC3细胞株。</p><fig position="float" id="F3"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.F003</object-id><label>图3</label><caption><title>LNCaP和PC3细胞系转染siRNA后各组的ARTN表达情况</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.3</label><title>ARTN expression in LNCaP and PC3 cell lines in each group after the transfection of siRNA</title></abstract><abstract abstract-type="note"><p>A： LNCaP cell line； B： PC3 cell line； <sup>**</sup><italic>P</italic>0.01 <italic>vs</italic> si-control group.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F003.eps" id="Graphic3"><?fx-imagestate width="134.76109314" height="68.43888855"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F003.jpg"><?fx-imagestate width="134.76109314" height="68.43888855"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F003c.jpg"><?fx-imagestate width="134.76109314" height="68.43888855"?></graphic></alternatives></fig></sec><sec id="s2d"><label>2.4</label><title>ARTN对PCa细胞增殖活性的影响</title><p specific-use="noneIndent">CCK-8实验结果显示，在LNCaP细胞中，转染后培养12 h，si-control组、siARTN-1组和siARTN-2组的细胞活力分别为1.714±0.118、1.767±0.234、3.425±0.217，实验组与对照组比较差异均无统计学意义；培养24 h的细胞活力分别为6.192±0.589、7.551±0.801、11.454±1.081，培养48 h的细胞活力分别为42.334±2.341、43.393±2.156、67.238±3.454，实验组与对照组比较差异均有统计学意义（ <italic>P</italic>0.01）。在PC3细胞中，转染后培养12 h，si-control组、siARTN-1组和siARTN-2组的细胞活力分别为2.442±0.271、3.103±0.196、4.978±0.358，实验组与对照组比较差异均无统计学意义；培养24 h的细胞活力分别为8.384±1.111、10.466±0.947、15.612±1.202，培养48 h的细胞活力分别为49.952±3.820、53.792±2.597、70.739±3.370，实验组与对照组比较差异均有统计学意义（<italic>P</italic>0.01）。</p></sec><sec id="s2e"><label>2.5</label><title>ARTN对PCa细胞迁移能力的影响</title><p specific-use="noneIndent">Transwell细胞迁移实验结果显示，在LNCaP和PC3细胞中，转染siRNA后，与对照组（si-control组）相比，实验组（siARTN-1组和siARTN-2组）的细胞迁移数目均明显减少，两组间的差异均有统计学意义（ <italic>P</italic>0.01），表明敲低ARTN可抑制PCa细胞的迁移能力。见<xref ref-type="fig" rid="F4">图4</xref>。</p><fig position="float" id="F4"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.F004</object-id><label>图4</label><caption><title>LNCaP和PC3细胞系转染siRNA后各组迁移细胞的数量    ×100</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig. 4</label><title>The number of migrated cells in each group after the transfection of siRNA into LNCaP and PC3 cell lines    ×100</title></abstract><abstract abstract-type="note"><p>A： LNCaP cell line； B： PC3 cell line； <sup>**</sup><italic>P</italic>0.01 <italic>vs</italic> si-control group.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F004.eps" id="Graphic4"><?fx-imagestate width="159.10276794" height="63.14722443"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F004.jpg"><?fx-imagestate width="159.10276794" height="63.14722443"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F004c.jpg"><?fx-imagestate width="159.10276794" height="63.14722443"?></graphic></alternatives></fig></sec><sec id="s2f"><label>2.6</label><title>ARTN对PCa细胞侵袭能力的影响</title><p specific-use="noneIndent">Transwell细胞侵袭实验结果显示，在LNCaP和PC3细胞中，转染siRNA后，与对照组（si-control组）相比，实验组（siARTN-1组和siARTN-2组）的细胞侵袭数目均明显减少，两组间的差异均有统计学意义（ <italic>P</italic>0.01），表明敲低ARTN可抑制PCa细胞的侵袭能力。见<xref ref-type="fig" rid="F5">图5</xref>。</p><fig position="float" id="F5"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.F005</object-id><label>图5</label><caption><title>LNCaP和PC3细胞系转染siRNA后各组侵袭细胞的数量    ×100</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.5</label><title>The number of invaded cells in each group after the transfection of siRNA into LNCaP and PC3 cell lines    ×100</title></abstract><abstract abstract-type="note"><p>A： LNCaP cell line； B： PC3 cell line； <sup>**</sup><italic>P</italic>0.01 <italic>vs</italic> si-control group.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F005.eps" id="Graphic5"><?fx-imagestate width="158.39723206" height="57.15000153"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F005.jpg"><?fx-imagestate width="158.39723206" height="57.15000153"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F005c.jpg"><?fx-imagestate width="158.39723206" height="57.15000153"?></graphic></alternatives></fig></sec><sec id="s2g"><label>2.7</label><title>ARTN对PCa细胞上皮-间质转化（epithelial-mesenchymal transition，EMT）相关蛋白表达的影响</title><p specific-use="noneIndent">Western blot检测ARTN对EMT相关标志物钙黏蛋白E（E-cadherin）、钙黏蛋白N（N-cadherin）、波形蛋白（Vimentin）、蜗牛家族转录抑制因子1（Snail-1）表达的影响。结果显示，LNCaP和PC3细胞系中实验组的E-cadherin蛋白表达水平高于对照组，而N-cadherin、Snail-1和Vimentin蛋白表达水平均低于对照组（<xref ref-type="fig" rid="F6">图6</xref>），表明实验组的EMT程度被抑制。</p><fig position="float" id="F6"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.03.009.F006</object-id><label>图6</label><caption><title>LNCaP和PC3细胞系转染siRNA后各组EMT相关蛋白的表达情况</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.6</label><title>Expression of EMT-related proteins in LNCaP and PC3 cell lines in each group after the transfection of siRNA</title></abstract><abstract abstract-type="note"><p>A： LNCaP cell line； B： PC3 cell line； <sup>**</sup><italic>P</italic>0.01 <italic>vs</italic> si-control group.</p></abstract><alternatives><graphic specific-use="print" xlink:href="media/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F006.eps" id="Graphic6"><?fx-imagestate width="156.98609924" height="110.41944885"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F006.jpg"><?fx-imagestate width="156.98609924" height="110.41944885"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/741FCECB-B72E-4329-992D-AF7A3FB8B10A-F006c.jpg"><?fx-imagestate width="156.98609924" height="110.41944885"?></graphic></alternatives></fig></sec></sec><sec id="s3"><label>3</label><title>讨论</title><p>ARTN作为GDNF家族的重要成员，在神经系统的施万（Schwann）细胞及其前体细胞中呈现高表达特征。该蛋白在神经系统发育和损伤修复过程中具有双重调控作用，既能影响神经元的定向迁移和轴突生长，又在神经再生机制中起关键作用<sup>［<xref ref-type="bibr" rid="R7">7</xref>］</sup>。研究<sup>［<xref ref-type="bibr" rid="R8">8</xref>］</sup>表明，ARTN在多种上皮源性肿瘤的发生发展过程中表现出复杂的生物学效应，其促癌作用日益受到学界关注。</p><p>有研究<sup>［<xref ref-type="bibr" rid="R9">9</xref>］</sup>表明，ARTN在多种恶性肿瘤组织中呈现过表达现象，该蛋白可通过调控多种信号通路网络，显著增强肿瘤细胞的增殖活性、侵袭潜能和转移能力。在宫颈癌的研究中表明，ARTN表达水平与患者远处转移率和复发率呈正相关性，下调ARTN表达可有效抑制宫颈癌细胞增殖和侵袭行为，其作用机制可能与AKT/mTOR信号通路的磷酸化激活密切相关<sup>［<xref ref-type="bibr" rid="R10">10</xref>］</sup>。胃癌相关研究显示，ARTN高表达患者往往表现出较差的无进展生存期；体外实验表明，通过基因敲除技术抑制ARTN表达后，STAT3蛋白的磷酸化水平明显降低，从而抑制胃癌细胞的DNA生物合成和增殖过程，同时该蛋白还能通过调控MMP-9和E-cadherin的表达水平来增强癌细胞的迁移侵袭能力<sup>［<xref ref-type="bibr" rid="R11">11</xref>］</sup>。在胰腺癌研究中，ARTN通过活化Akt和ERK1/2/NF-κB信号级联反应，诱导CXCR4的表达上调，进而通过调控SDF-1α/CXCR4信号轴来增强胰腺癌细胞的转移和侵袭特性。这些研究提示，ARTN可能成为抑制胰腺癌神经浸润和远处转移的新型治疗靶点<sup>［<xref ref-type="bibr" rid="R12">12</xref>］</sup>。</p><p>为了探究ARTN在PCa中的作用及机制，本研究对91例PCa组织的免疫组化分析，显示ARTN蛋白在超过半数的肿瘤组织（52/91）中呈现明显的细胞质/膜定位高表达。进一步分析显示，ARTN的高表达水平与Gleason评分、淋巴结转移、局部神经侵犯以及患者生存期缩短存在相关性，表明该蛋白可能作为评估PCa预后的重要指标。为深入探究ARTN在PC患者疾病进展过程中的生物学功能，本研究选取了LNCaP（雄激素敏感型）和PC3（雄激素抵抗型）这两种具有不同特性的PCa细胞系作为实验对象，以覆盖激素敏感型和激素抵抗型这两类PCa患者。构建ARTN低表达的细胞模型后，细胞增殖和Transwell实验结果表明，该蛋白能够明显促进PCa细胞的生长和转移能力，这为阐明PCa发生和发展的分子机制提供了新的研究方向。</p><p>在肿瘤演进过程中，EMT是一个关键的生物学过程，它不仅参与组织形态的塑造，还在肿瘤细胞的恶性转化和远处转移中起重要作用<sup>［<xref ref-type="bibr" rid="R13">13</xref>］</sup>。特别是在PCa的发展过程中，EMT的激活与疾病进展密切相关<sup>［<xref ref-type="bibr" rid="R14">14</xref>］</sup>。为探讨ARTN影响PCa进展的机制，本研究检测了EMT相关标志物的表达变化。实验结果表明，下调ARTN表达可导致上皮标志物E-cadherin表达增加，同时降低间质标志物N-cadherin、Snail-1和Vimentin的表达水平，提示ARTN可能通过调控EMT过程来影响PCa的侵袭转移能力。有文献<sup>［<xref ref-type="bibr" rid="R15">15</xref>］</sup>表明，阻断EMT过程可有效抑制PCa细胞的恶性表型，其具体的分子机制可能涉及AKT/mTOR、NF-κB等多种分子机制和信号通路，另有文献报道，ARTN与AKT/mTOR<sup>［<xref ref-type="bibr" rid="R10">10</xref>］</sup>、NF-κB<sup>［<xref ref-type="bibr" rid="R12">12</xref>］</sup>和Twist1/Bcl2<sup>［<xref ref-type="bibr" rid="R16">16</xref>］</sup>等信号通路存在着调节关系，这提示ARTN有可能通过调控这些分子通路进而影响PCa的EMT进程。ARTN可能是通过诱导EMT，进而推动PCa进展的一个关键因子。</p></sec></body><back><ref-list><title>参考文献</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Siegel</surname><given-names>R L</given-names></name>， <name name-style="eastern"><surname>Kratzer</surname><given-names>T B</given-names></name>， <name name-style="eastern"><surname>Giaquinto</surname><given-names>A N</given-names></name>， <etal>et al</etal></person-group>. <article-title>Cancer statistics， 2025</article-title>［J］. <source>CA Cancer J Clin</source>， <year>2025</year>， <volume>75</volume>（<issue>1</issue>）： <fpage>10</fpage>-<lpage>45</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3322/caac.21871">10.3322/caac.21871</ext-link></comment>.</mixed-citation></ref><ref id="R2"><label>2</label><citation-alternatives><mixed-citation publication-type="journal" publication-format="print"><person-group><string-name>郑荣寿</string-name>， <string-name>陈　茹</string-name>， <string-name>韩冰峰</string-name>， <etal>等</etal></person-group>. <article-title>2022年中国恶性肿瘤流行情况分析</article-title>［J］. <source>中华肿瘤杂志</source>， <year>2024</year>， <volume>46</volume>（<issue>3</issue>）： <fpage>221</fpage>-<lpage>31</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3760/cma.j.cn112152-20240119-00035">10.3760/cma.j.cn112152-20240119-00035</ext-link></comment>.</mixed-citation><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zheng</surname><given-names>R S</given-names></name>， <name name-style="eastern"><surname>Chen</surname><given-names>R</given-names></name>， <name name-style="eastern"><surname>Han</surname><given-names>B F</given-names></name>， <etal>et al</etal></person-group>. <article-title>Cancer incidence and mortality in China， 2022</article-title>［J］. <source>Chin J Oncol</source>， <year>2024</year>， <volume>46</volume>（<issue>3</issue>）： <fpage>221</fpage>-<lpage>31</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3760/cma.j.cn112152-20240119-00035">10.3760/cma.j.cn112152-20240119-00035</ext-link></comment>.</mixed-citation></citation-alternatives></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Wang</surname><given-names>B</given-names></name>， <name name-style="eastern"><surname>Liu</surname><given-names>Z</given-names></name>， <name name-style="eastern"><surname>Yang</surname><given-names>L</given-names></name>， <etal>et al</etal></person-group>. <article-title>Advances in the treatment of metastatic prostate cancer in China</article-title>［J］. <source>Cancer Biol Med</source>， <year>2025</year>， <volume>22</volume>（<issue>5</issue>）： <fpage>433</fpage>-<lpage>8</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.20892/j.issn.2095-3941.2025.0065">10.20892/j.issn.2095-3941.2025.0065</ext-link></comment>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Baloh</surname><given-names>R H</given-names></name>， <name name-style="eastern"><surname>Tansey</surname><given-names>M G</given-names></name>， <name name-style="eastern"><surname>Lampe</surname><given-names>P A</given-names></name>， <etal>et al</etal></person-group>. <article-title>Artemin， a novel member of the GDNF ligand family， supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex</article-title>［J］. <source>Neuron</source>， <year>1998</year>， <volume>21</volume>（<issue>6</issue>）： <fpage>1291</fpage>-<lpage>302</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1016/s0896-6273（00）80649-2">10.1016/s0896-6273（00）80649-2</ext-link></comment>.</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Hezam</surname><given-names>K</given-names></name>， <name name-style="eastern"><surname>Jiang</surname><given-names>J</given-names></name>， <name name-style="eastern"><surname>Sun</surname><given-names>F</given-names></name>， <etal>et al</etal></person-group>. <article-title>Artemin promotes oncogenicity， metastasis and drug resistance in cancer cells</article-title>［J］. <source>Rev Neurosci</source>， <year>2018</year>， <volume>29</volume>（<issue>1</issue>）： <fpage>93</fpage>-<lpage>8</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1515/revneuro-2017-0029">10.1515/revneuro-2017-0029</ext-link></comment>.</mixed-citation></ref><ref id="R6"><label>6</label><citation-alternatives><mixed-citation publication-type="journal" publication-format="print"><person-group><string-name>张鹤瑞</string-name>， <string-name>韦之见</string-name>， <string-name>罗盼权</string-name>， <etal>等</etal></person-group>. <article-title>SATB1和EGFR在胃癌中的功能及其临床意义</article-title>［J］. <source>安徽医科大学学报</source>， <year>2024</year>， <volume>59</volume>（<issue>8</issue>）： <fpage>1476</fpage>-<lpage>82</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2024.08.028">10.19405/j.cnki.issn1000-1492.2024.08.028</ext-link></comment>.</mixed-citation><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zhang</surname><given-names>H R</given-names></name>， <name name-style="eastern"><surname>Wei</surname><given-names>Z J</given-names></name>， <name name-style="eastern"><surname>Luo</surname><given-names>P Q</given-names></name>， <etal>et al</etal></person-group>. <article-title>Function and clinical significance of SATB1 and EGFR in gastric cancer</article-title>［J］. <source>Acta Univ Med Anhui</source>， <year>2024</year>， <volume>59</volume>（<issue>8</issue>）： <fpage>1476</fpage>-<lpage>82</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2024.08.028">10.19405/j.cnki.issn1000-1492.2024.08.028</ext-link></comment>.</mixed-citation></citation-alternatives></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zhu</surname><given-names>S</given-names></name>， <name name-style="eastern"><surname>Li</surname><given-names>Y</given-names></name>， <name name-style="eastern"><surname>Bennett</surname><given-names>S</given-names></name>， <etal>et al</etal></person-group>. <article-title>The role of glial cell line-derived neurotrophic factor family member artemin in neurological disorders and cancers</article-title>［J］. <source>Cell Prolif</source>， <year>2020</year>， <volume>53</volume>（<issue>7</issue>）： <elocation-id>e12860</elocation-id>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1111/cpr.12860">10.1111/cpr.12860</ext-link></comment>.</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Fielder</surname><given-names>G C</given-names></name>， <name name-style="eastern"><surname>Yang</surname><given-names>T W</given-names></name>， <name name-style="eastern"><surname>Razdan</surname><given-names>M</given-names></name>， <etal>et al</etal></person-group>. <article-title>The GDNF family： a role in cancer？</article-title>［J］. <source>Neoplasia</source>， <year>2018</year>， <volume>20</volume>（<issue>1</issue>）： <fpage>99</fpage>-<lpage>117</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1016/j.neo.2017.10.010">10.1016/j.neo.2017.10.010</ext-link></comment>.</mixed-citation></ref><ref id="R9"><label>9</label><citation-alternatives><mixed-citation publication-type="journal" publication-format="print"><person-group><string-name>张洪亮</string-name>， <string-name>刘昊天</string-name>， <string-name>刘俊阳</string-name>， <etal>等</etal></person-group>. <article-title>ARTN通过PI3K/Akt通路促进恶性外周神经鞘瘤细胞的增殖和侵袭</article-title>［J］. <source>中华肿瘤杂志</source>， <year>2025</year>， <volume>47</volume>（<issue>2</issue>）： <fpage>149</fpage>-<lpage>59</lpage>. <comment>doi： <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3760/cma.j.cn112152-20240531-00229">10.3760/cma.j.cn112152-20240531-00229</ext-link></comment>.</mixed-citation><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zhang</surname><given-names>H L</given-names></name>， <name name-style="eastern"><surname>Liu</surname><given-names>H T</given-names></name>， <name name-style="eastern"><surname>Liu</surname><given-names>J Y</given-names></name>， <etal>et al</etal></person-group>. <article-title>Artemin promotes proliferation and invasion of malignant peripheral nerve sheath tumor cells through the PI3K/Akt pathway</article-title>［J］. <source>Chin J Oncol</source>， <year>2025</year>， <volume>47</volume>（<issue>2</issue>）： <fpage>149</fpage>-<lpage>59</lpage>. <comment>doi： <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3760/cma.j.cn112152-20240531-00229">10.3760/cma.j.cn112152-20240531-00229</ext-link></comment>.</mixed-citation></citation-alternatives></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Zhu</surname><given-names>M</given-names></name>， <name name-style="eastern"><surname>Zhou</surname><given-names>L</given-names></name>， <name name-style="eastern"><surname>Fu</surname><given-names>J</given-names></name>， <etal>et al</etal></person-group>. <article-title>Artemin promotes the migration and invasion of cervical cancer cells through AKT/mTORC1 signaling</article-title>［J］. <source>J Oncol</source>， <year>2022</year>， <volume>2022</volume>： <fpage>3332485</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1155/2022/3332485">10.1155/2022/3332485</ext-link></comment>.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Jiang</surname><given-names>X</given-names></name>， <name name-style="eastern"><surname>Chen</surname><given-names>K</given-names></name>， <name name-style="eastern"><surname>Fan</surname><given-names>K</given-names></name>， <etal>et al</etal></person-group>. <article-title>Prognostic significance of artemin in gastric cancer and its role in tumorigenesis</article-title>［J］. <source>Transl Cancer Res</source>， <year>2020</year>， <volume>9</volume>（<issue>1</issue>）： <fpage>12</fpage>-<lpage>20</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.21037/tcr.2019.11.13">10.21037/tcr.2019.11.13</ext-link></comment>.</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Wang</surname><given-names>J</given-names></name>， <name name-style="eastern"><surname>Wang</surname><given-names>H</given-names></name>， <name name-style="eastern"><surname>Cai</surname><given-names>J</given-names></name>， <etal>et al</etal></person-group>. <article-title>Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF-κB signaling</article-title>［J］. <source>Exp Cell Res</source>， <year>2018</year>， <volume>365</volume>（<issue>1</issue>）： <fpage>12</fpage>-<lpage>23</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1016/j.yexcr.2018.02.008">10.1016/j.yexcr.2018.02.008</ext-link></comment>.</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Yang</surname><given-names>J</given-names></name>， <name name-style="eastern"><surname>Antin</surname><given-names>P</given-names></name>， <name name-style="eastern"><surname>Berx</surname><given-names>G</given-names></name>， <etal>et al</etal></person-group>. <article-title>Guidelines and definitions for research on epithelial-mesenchymal transition</article-title>［J］. <source>Nat Rev Mol Cell Biol</source>， <year>2020</year>， <volume>21</volume>（<issue>6</issue>）： <fpage>341</fpage>-<lpage>52</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41580-020-0237-9">10.1038/s41580-020-0237-9</ext-link></comment>.</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Wei</surname><given-names>X</given-names></name>， <name name-style="eastern"><surname>Liu</surname><given-names>R</given-names></name>， <name name-style="eastern"><surname>Li</surname><given-names>W</given-names></name>， <etal>et al</etal></person-group>. <article-title>Advances in research regarding epithelial-mesenchymal transition and prostate cancer</article-title>［J］. <source>Front Cell Dev Biol</source>， <year>2025</year>， <volume>13</volume>： <fpage>1583255</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3389/fcell.2025.1583255">10.3389/fcell.2025.1583255</ext-link></comment>.</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Xie</surname><given-names>Q</given-names></name>， <name name-style="eastern"><surname>Hu</surname><given-names>Y</given-names></name>， <name name-style="eastern"><surname>Zhang</surname><given-names>C</given-names></name>， <etal>et al</etal></person-group>. <article-title>Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation</article-title>［J］. <source>Cancer Cell Int</source>， <year>2024</year>， <volume>24</volume>（<issue>1</issue>）： <fpage>303</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1186/s12935-024-03483-2">10.1186/s12935-024-03483-2</ext-link></comment>.</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Banerjee</surname><given-names>A</given-names></name>， <name name-style="eastern"><surname>Qian</surname><given-names>P</given-names></name>， <name name-style="eastern"><surname>Wu</surname><given-names>Z S</given-names></name>， <etal>et al</etal></person-group>. <article-title>Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells</article-title>［J］. <source>J Biol Chem</source>， <year>2012</year>， <volume>287</volume>（<issue>51</issue>）： <fpage>42502</fpage>-<lpage>15</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1074/jbc.M112.365163">10.1074/jbc.M112.365163</ext-link></comment>.</mixed-citation></ref></ref-list><fn-group><fn fn-type="other" specific-use="citation-format"><p>李容, 井俊峰, 魏灿. ARTN在前列腺癌中的表达及临床意义[J]. 安徽医科大学学报, 2026, 61(03): 448-454.</p></fn><fn fn-type="other" specific-use="citation-format" xml:lang="en"><p>Li Rong, Jing Junfeng, Wei Can. Expression and clinical significance of ARTN in prostate cancer[J]. Acta Universitatis Medicinalis Anhui, 2026, 61(03): 448-454.</p></fn></fn-group></back></article>